the dose escalation question that gets asked weekly, answered properly
the dose escalation question that gets asked weekly, answered properly. Making the case below, and I expect to lose some of it in the comments. Stopped at a low step because there was no reason to go further and no data to tell me what further would do. The thing that surprised me was how much of the discussion here…
Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.
the glucagon component is why the metabolic story reads differently
Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.
Sceptical of the extrapolation.
Adding the standing caveat: none of this is approved anywhere and research material is not for human use.
Agreed, and the framing that helps is: this is a phase 2 compound with phase 3 running. Everything else is inference.